Randomized Phase II Neoadjuvant Comparison Between Letrozole, Anastrozole, and Exemestane for Postmenopausal Women With Estrogen Receptor–Rich Stage 2 to 3 Breast Cancer: Clinical and Biomarker Outcomes and Predictive Value of the Baseline PAM50-Based Intrinsic Subtype—ACOSOG Z1031

PURPOSE: Preoperative aromatase inhibitor (AI) treatment promotes breast-conserving surgery (BCS) for estrogen receptor (ER) –positive breast cancer. To study this treatment option, responses to three AIs were compared in a randomized phase II neoadjuvant trial designed to select agents for phase II...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
Main Authors: Ellis, Matthew J., Suman, Vera J., Hoog, Jeremy, Lin, Li, Snider, Jacqueline, Prat, Aleix, Parker, Joel S., Luo, Jingqin, DeSchryver, Katherine, Allred, D. Craig, Esserman, Laura J., Unzeitig, Gary W., Margenthaler, Julie, Babiera, Gildy V., Marcom, P. Kelly, Guenther, Joseph M., Watson, Mark A., Leitch, Marilyn, Hunt, Kelly, Olson, John A.
פורמט: Artigo
שפה:Inglês
יצא לאור: American Society of Clinical Oncology 2011
נושאים:
Original Reports
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC3107749/
https://ncbi.nlm.nih.gov/pubmed/21555689
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2010.31.6950
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים